Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives

  • Angelis Konstantinopoulos Department of Urology, University Hospital of Patras, Greece.
  • Konstantinos Giannitsas Department of Urology, University Hospital of Patras, Greece.
  • Spiros Raptis Department of Urology, University Hospital of Patras, Greece.
  • Petros Perimenis Department of Urology, University Hospital of Patras, Greece.
Keywords: Endothelial dysfunction, erectile dysfunction, phosphodiesterase 5 inhibitors

Abstract

Endothelial dysfunction is a pathological entity that multiply affects the health status. Erectile dysfunction is being recognized as a condition that is strongly interrelated with endothelial dysfunction, being a vascular event itself. Oral pharmacotherapy for erectile dysfunction has provided us with a new armamentarium on this condition. Phosphodiesterase 5 inhibitors have been investigated and proved useful in clinical practice for erectile dysfunction but in addition to this, the results seem promising of a beneficial effect on endothelial dysfunction, as well.
Published
2007-01-01
How to Cite
KonstantinopoulosA., GiannitsasK., RaptisS., & PerimenisP. (2007). Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives. Drug Target Insights, 2(1). https://doi.org/10.33393/dti.2007.1310